Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

OncoImmunology

Volumn 6, Issue 12, 2017, Pages

  Yuan, Yuan ^a   Kos, Ferdynand J ^a   He, Ting Fang ^a   Yin, Hongwei H ^a   Li, Mengsha ^a   Hardwick, Nicola ^a   Zurcher, Kathryn ^a   Schmolze, Daniel ^a   Lee, Peter ^a   Pillai, Raju K ^a   Chung, Vincent ^a   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

immunotherapy; MVA; p53; PD 1; pembrolizumab; T cell response; triple negative breast cancer; vaccine; vaccinia

Indexed keywords

CAPECITABINE; CARBOPLATIN; CD134 ANTIGEN; CD137 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ERIBULIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; P53MVA; PEMBROLIZUMAB; TRANSCRIPTION FACTOR C MAF; TRANSCRIPTION FACTOR T BET; TRANSCRIPTOME; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; AGED; ARTICLE; BACKACHE; BONE SCINTISCANNING; CANCER REGRESSION; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTRAMEDULLARY NAILING; LYMPHOCYTIC INFILTRATION; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROTEIN EXPRESSION; PUNCH BIOPSY; QUALITY OF LIFE; RASH; SKIN BIOPSY; SKIN DEFECT; SKIN METASTASIS; THROMBOCYTOPENIA; TRANSGENE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; VOMITING; X-RAY COMPUTED TOMOGRAPHY;

EID: 85032687305     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1363138     Document Type: Article

References (20)

1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Rev Clin Oncol. 2016;13(11):674-90. doi:10.1038/nrclinonc.2016.66. PMID:27184417
2. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-40. doi:10.1158/1078-0432.CCR-13-0799. PMID:23948975
3. Arpino G, Generali D, Sapino A, Del Mastro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, et al. Gene expression profiling in breast cancer: a clinical perspective. Breast. 2013;22(2):109-20. doi:10.1016/j.breast.2013.01.016. PMID:23462680
4. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. doi:10.1101/cshperspect.a001008. PMID:20182602
5. Bueter M, Gasser M, Lebedeva T, Benichou G, Waaga-Gasser AM. Influence of p53 on anti-tumor immunity (review). Int J Oncol. 2006;28(2):519-25. PMID:16391808
6. Song GY, Gibson G, Haq W, Huang EC, Srivasta T, Hollstein M, Daftarian P, Wang Z, Diamond D, Ellenhorn JD. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother. 2007;56(8):1193-205. doi:10.1007/s00262-006-0270-3. PMID:17219151
7. Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer Invest. 2011;29(8):501-10. doi:10.3109/07357907.2011.606248. PMID:21843052
8. Liu X, Peralta EA, Ellenhorn JD, Diamond DJ. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res. 2000;60(3);693-701. PMID: 10676655
9. + T-cell responses. Clin Cancer Res. 2014;20(17):4459-70. doi:10.1158/1078-0432.CCR-13-3361. PMID:24987057
10. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361-70. doi:10.1158/2326-6066.CIR-13-0127. PMID:24764583
11. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraia K, Aktan G, Cheng JD, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460-7. doi:10.1200/JCO.2015.64.8931. PMID:27138582
12. Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Kramer B, Grischke EM, Brucker SY. PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care. 2016;11(6):385-90. doi:10.1159/000453569. PMID:28228704
13. Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology. 2014;3(10):e958949. doi:10.4161/21624011.2014.958949. PMID:25941580
14. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275-87. doi:10.1038/nrc.2016.36. PMID:27079802
15. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-9. doi:10.1038/nature10933. PMID:22495314
16. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412. PMID:23000897
17. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268-86. doi:10.1101/gad.190678.112. PMID:22713868
18. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423-7. doi:10.1126/science.aaf0683. PMID:28280249
19. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-33. doi:10.1126/science.aaf1292. PMID:28280247
20. Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2024;70(1):46-58. doi:10.1016/j.ymeth.2014.08.016. PMID:25242720